Kyu Y. Rhee is a Professor of Medicine and Professor of Microbiology and Immunology at Weill Cornell Medical College . His research focuses on Mycobacterium tuberculosis , with emphasis on metabolic pathways , antibiotic resistance mechanisms , and drug development . Research highlights include: Multi-omic approaches to TB drug discovery Mechanistic studies of antibiotic action Deciphering TB transmission genetics Metabolomics-driven target identification Current funding includes: Bill & Melinda Gates Foundation : AI/ML-assisted bacterial permeability platform National Institute of Allergy & Infectious Diseases : UM1 TB drug regimen design consortium National Heart, Lung, & Blood Institute : Studies on M. tuberculosis PE/PPE proteins and fructose-induced cancer He has authored over 50 publications on TB metabolomics, drug development, and pathogen persistence. His work bridges systems biology , chemical biology , and clinical research to address antimicrobial resistance.
Shutao Ma is a Professor and Doctoral Supervisor at Shandong University's School of Pharmaceutical Sciences, serving as Director of the Department of Medicinal Chemistry since 2009. He has received the Special Government Allowance from China's State Council since 2002 and the seventh youth award of Shandong province for his contributions to medicinal chemistry. His academic credentials include: Ph.D. in Pharmaceutical Sciences, Shandong University (2004-2007) M.Sc. in Pharmaceutical Sciences, Shandong Medical University (1988-1991) B.Sc. in Pharmaceutical Sciences, Shandong Medical University (1981-1986) Professor Ma's research pioneers innovative strategies against antibiotic-resistant bacteria through three interconnected pillars: 1) Designing FtsZ/AcrB-targeted small molecules to disrupt bacterial cell division and efflux mechanisms; 2) Structural optimization of macrolides, glycopeptides, and lipopeptides to overcome resistance; 3) Total synthesis and mechanistic studies of marine-derived antibacterial natural products. His work bridges synthetic chemistry with microbiological validation to develop next-generation antimicrobials. Analysis of his 15 most recent publications (2014-2016) reveals a dominant focus on antibacterial drug discovery (87% of works), particularly FtsZ inhibitors (33%) and macrolide derivatives (27%). Emerging themes include quorum sensing modulation (7%) and antiviral/anticancer applications (13%), demonstrating strategic expansion while maintaining core expertise in resistance mechanisms. His scientific recognition includes: First prize of Shandong science and technology progress award (2000) Special government allowance from the State Council (2002) The seventh youth awards of Shandong province (2002) As a Doctoral Supervisor, Professor Ma mentors the next generation of medicinal chemists while directing a robust research program funded by 12 major grants. His National Natural Science Foundation portfolio (2004-2020) spans antibacterial discovery, while Shandong Provincial grants (2006-2017) and China-Australia collaborations (2014-2017) support translational development of resistance-breaking agents. Leading the Department of Medicinal Chemistry, he oversees a multidisciplinary team integrating synthetic chemistry, microbiology, and computational modeling to advance antibacterial drug candidates from concept to preclinical validation, with particular emphasis on FtsZ-targeted therapeutics and macrolide engineering.
Dr. Andrew Bassett serves as Head of the Cellular and Gene Editing Research group at the Wellcome Sanger Institute, where he develops cutting-edge genome engineering techniques using human pluripotent stem cells to investigate neurodegenerative diseases including Alzheimer's and Parkinson's. His work focuses on scaling genetic screening approaches and improving CRISPR specificity for modeling complex disease mechanisms. His academic training includes: PhD at the MRC Laboratory of Molecular Biology (MRC-LMB) with Andrew Travers on chromatin remodelling in heterochromatin formation Postdoctoral research with David Baulcombe at the University of Cambridge studying small RNA roles in chromatin modification Additional postdoctoral work with Chris Ponting at the MRC Functional Genomics Unit (MRC-FGU) in Oxford, where he pioneered CRISPR applications in Drosophila Bassett's research program centers on developing advanced genome engineering methodologies for precise modulation of gene expression networks during development and neurodegeneration. His group specializes in creating complex editing events (SNPs, paired knockouts, enhancer perturbations) within iPSC-derived models, with particular emphasis on epigenetic regulation and transcriptional control. Current projects integrate single-cell 'omics and phenotypic assays to decode genetic causes of neurodegenerative disorders through the OpenTargets consortium. Analysis of his 15 most recent publications reveals dominant trends in CRISPR technology development (35%), neurodegenerative disease modeling (30%), and single-cell functional genomics (25%). His work consistently bridges methodological innovation with disease mechanism studies, increasingly incorporating multi-omics approaches and expanding into cancer immunology and infectious disease applications since 2022. As group leader, Bassett mentors postdoctoral researchers and PhD students while securing major funding for genome engineering initiatives. His team operates within the Sanger Institute's Cellular Operations division and maintains critical partnerships with the OpenTargets consortium for therapeutic target validation. The laboratory specializes in high-throughput screening platforms using iPSC-derived neural and microglial models, with recent methodological advances including scSNV-seq and ONE-STEP tagging systems that significantly enhance precision genome editing capabilities.
Yuri Y. Gleba is a renowned academic scientist affiliated with the Institute of Cell Biology and Genetic Engineering at the Ukrainian Academy of Sciences in Kiev, Ukraine. As Founder and Director (1989–2010) and current Honorary Director, he has shaped plant biotechnology research through pioneering work in transient expression systems and molecular farming. Key Roles: Founder and Director of Institute of Cell Biology and Genetic Engineering (1989–2010), Honorary Director (2010–present) Research Interests Plant genetics , plant physiology , and biotechnology underpin his work in genetic engineering , viral vector systems , and transgenic plant applications . His innovations include the Magnifection platform for rapid plant-based vaccine production and methods for RNA silencing enhancement in molecular farming. Scientific Recognition includes membership in six international academies (World Academy of Arts and Science, Academia Europaea, Leopoldina, Ukrainian Academy of Sciences, Lithuanian Academy of Science, Bavarian Academy of Sciences) and prestigious awards like the Koerber Prize , A. von Humboldt Prize , and state prizes from the USSR and Ukraine. His work has appeared in top journals including Proceedings of the National Academy of Sciences USA and FEBS Letters . Publications : Gleba's 15 most recent articles (2004–2010) focus on plant biotechnology applications, viral vector engineering, and molecular farming. Key trends include plant-based pharmaceutical production , transient expression systems , and transgene containment strategies . Laboratory and Collaborations : Founded and led the Institute of Cell Biology and Genetic Engineering, fostering international collaborations in plant biotechnology and genetic engineering research.
Claudio R. Alarcón is an Associate Professor in Pharmacology at Yale University School of Medicine. His research focuses on RNA metabolism's role in development, health, and disease, particularly RNA modifications and non-coding RNAs. He joined Yale in 2017 after postdoctoral training at The Rockefeller University and holds a PhD from Cornell University (2009) and a BSc from Pontificia Universidad Católica de Chile (1999). Research Interests: Functional roles of m6A RNA modifications MicroRNA biogenesis and cancer progression Non-coding RNA regulation in metastasis Key Appointments: Primary Faculty, Yale Cancer Biology Institute Member, Yale Cancer Center Faculty, Yale Combined Program in Biological and Biomedical Sciences His lab integrates bioinformatics, molecular, and cellular approaches to study cancer metastasis mechanisms, including miRNA processing disruptions and SOX4/TMEM2 pathways linked to clinical outcomes.
Shabaz Mohammed is an Associate Professor of Proteomics at the University of Oxford, holding joint appointments in the Departments of Chemistry and Biochemistry. Since 2020, he has served as Head of the Mechanistic Proteomics research programme at the Rosalind Franklin Institute. His research focuses on advancing proteomics technologies to study protein post-translational modifications and their roles in cellular processes, with applications in viral infections and disease mechanisms. Education: BSc in Chemistry, UMIST (now The University of Manchester), 1999 PhD in Biological Mass Spectrometry, University of Manchester, 2003 Postdoctoral Research, University of Southern Denmark (with Ole Jensen), 2005-2008 Postdoctoral Research, Utrecht University (with Albert Heck), 2008 Professor Mohammed's research centers on developing novel mass spectrometry approaches for large-scale characterization of protein post-translational modifications (PTMs). His group innovates in chromatographic techniques for single-cell proteomics, creates materials for PTM enrichment (glycosylation/phosphorylation), and applies these tools to study viral infections (SARS-CoV-2), cell cycle regulation, and signaling pathways. His work bridges chemistry, biochemistry, and cell biology to understand dynamic protein functions in health and disease. His recent publications (2023-2025) demonstrate strong emphasis on viral proteomics, particularly virus-host RNA-binding protein interactions, and innovations in mass spectrometry fragmentation techniques and chromatography. Key themes include viral remodeling of host cells, new labeling strategies for PTMs, and advancements in single-cell proteomics, with significant implications for understanding viral pathogenesis. Scientific Awards: No specific awards or fellowships were detailed in the source material. Advising and Grants: Information regarding graduate students supervised or specific research grants was not provided in the available text. As an active research group leader, Professor Mohammed likely mentors PhD students and secures competitive funding for proteomics research. Laboratories and Collaborations: Professor Mohammed leads a research group at Oxford focused on proteomics technology development. He collaborates extensively with the Ben Davis group on PTM detection materials and across the university on biochemical applications. At the Rosalind Franklin Institute, he heads the Mechanistic Proteomics programme to unravel protein functions through advanced proteomic methods.
Michael Boutros is a Full Professor at Heidelberg University and Head of Division at the German Cancer Research Center (DKFZ). He currently serves as Dean of the Medical Faculty at Heidelberg University (since 2023) and Director of the Marsilius Kolleg (since 2020). He has held leadership roles including Coordinator of the Functional and Structural Genomics Program at DKFZ (2014–2023) and Acting Scientific Director (2015–2016). His academic base is within the Medical Faculty, focusing on molecular oncology and functional genomics. PhD, Witten/Herdecke University (1993–1996) Postdoctoral Research, Harvard Medical School (1999–2003) MPA, John F. Kennedy School of Government, Harvard University (1999–2001) Additional training: Cold Spring Harbor Laboratory, SUNY Stony Brook His research centers on Wnt signaling, functional genomics, and cancer pathways. He leads major research initiatives such as CRC 1324 on Wnt signaling and the ERC Synergy Grant DECODE. His work integrates high-throughput screening, CRISPR, and systems biology to dissect signaling networks in cancer and development. He has pioneered genome-wide RNAi and CRISPR screens to identify novel regulators of Wnt signaling across models. The 15 most recent articles reflect a strong focus on Wnt pathway regulation using functional genomics in both Drosophila and mammalian systems. Themes include high-throughput screening, CRISPR-based validation, cross-species conservation, and therapeutic targeting. Keywords span Cancer Biology, Systems Biology, and Signal Transduction, with subfields like RNAi, ubiquitination, stem cell regulation, and machine learning in image analysis. Michael Boutros has received numerous scientific honors: Elected member, Leopoldina National Academy of Sciences (2022) Elected member, Heidelberg Academy of Sciences (2022) EMBO Member (2013) ERC Advanced Grant (2012) Johann-Georg Zimmermann Research Award (2007) EMBO Young Investigator (2005) Member, 'Die Junge Akademie' (2003) He has been a recipient of the Emmy-Noether Program, McCloy Fellowship, Boehringer Ingelheim PhD Fellowship, Studienstiftung Fellowship, and Fulbright Fellowship. As a mentor and research leader, he has supervised numerous early-career scientists and coordinated large collaborative grants including the FP7 'CancerPathways' project. He currently serves as Speaker of the Research and Strategy Commission at Heidelberg University and Managing Director of the Health and Life Science Alliance Heidelberg Mannheim. He leads the CRC 1324 on Wnt signaling and is Coordinating PI of the ERC Synergy Grant DECODE. He is also Spokesperson of DFG Research Group 1036 and Coordinator of the former FP7 Coordinated Project 'CancerPathways'. His lab employs cutting-edge functional genomics tools to decode signaling networks in cancer and development.
Miler T. Lee is an Associate Professor at the University of Pittsburgh , focusing on gene regulation during early embryonic development through high-throughput experimental and computational genomics. He earned his Ph.D. in Genomics and Computational Biology in 2009 from the University of Pennsylvania under Dr. Junhyong Kim, followed by postdoctoral work with Dr. Antonio Giraldez at Yale University. Joining the university in 2016, his research spans maternal-to-zygotic transition (MZT), RNA stability, pluripotency networks, and evolutionary developmental biology, utilizing model organisms like zebrafish, Xenopus, and Hydractinia symbiolongicarpus. Key Research Themes: Maternally inherited RNA dynamics during embryogenesis Mechanisms of RNA degradation and transcriptome remodeling Evolution of pluripotency networks in hybrid species Role of zinc signaling in fertilization barriers Computational tools for RNA regulation and sensing Scientific Awards: Pan-American Society for Evolutionary Developmental Biology Junior Faculty Award (2024) Outstanding New Investigator – International Xenopus Board (2023) Basil O'Connor Scholar – March of Dimes (2017-2019) Recent publications highlight his work on enhancer classification, RNA degradation mechanisms, and cross-species MZT comparisons. His lab develops innovative methods like RESA for regulatory sequence analysis and studies evolutionary divergence in RNA localization patterns. While the articles span computational and experimental approaches, they consistently address RNA's role in cellular identity, developmental timing, and evolutionary adaptation. Applications include understanding pluripotency, designing RNA biosensors, and elucidating fertilization barriers. Prospective Ph.D. students are encouraged to contact him for opportunities in gene regulation, development, evo-devo, and computational genomics.
David B. Bensimon is a world-leading biophysicist and Professor in the Department of Chemistry and Biochemistry at the University of California, Los Angeles, holding the prestigious Regent's Professor title since 2007. He maintains a dual academic position, serving as Directeur de Recherche at the French National Center for Scientific Research (CNRS) at the Ecole Normale Supérieure (ENS) in Paris while teaching and conducting research at UCLA for one quarter each year. His academic journey began with a Ph.D. from the University of Chicago in 1986 under Leo Kadanoff, followed by postdoctoral research at Bell Laboratories and ENS Paris. Professor Bensimon's research spans multiple frontiers in biophysics and molecular biology, with particular expertise in single-molecule studies of nucleic acids and their proteins. His laboratory pioneered the Magnetic Trap technique for manipulating individual DNA molecules, enabling groundbreaking investigations into DNA mechanics, topoisomerase interactions, and molecular combing. His recent work has expanded into optogenetics, developmental biology using zebrafish models, and cancer research, with significant contributions to understanding how single-cell oncogene activation leads to tumorigenesis. His research output shows remarkable breadth across disciplines, with recent publications spanning biophysics, developmental biology, cancer research, and genomic technology development. Bensimon's work on opto-chemical tools has particularly transformed how researchers can control biological processes with unprecedented spatiotemporal precision, especially in zebrafish models. His laboratory has developed photoactivatable versions of key molecular tools including Cas9 (OptoCas9) and cyclofen systems that allow precise control of protein activity at the single-cell level. 2007 Regent's Professor at UCLA 1997 Vinci of Excellence Award for phospholipid vesicle research 1994 Jacques Monod Prize for Molecular Combing discovery Special Prize of the French Physical Society for DNA mechanics work ICAM Fellow KITP-UCSB Representative Bensimon has made significant contributions to both basic science and translational applications, co-founding Depixus for nucleic acid sequencing and epigenetic analysis. His laboratory continues to push boundaries in single-molecule biophysics while expanding into developmental biology and cancer research, with recent work demonstrating that activation of kRas in dedifferentiated cells increases tumorigenesis probability by two orders of magnitude. His mentorship has produced notable researchers including X. Michalet, and his theoretical work extends to the philosophical unification of scientific disciplines as evidenced by his book "The Unity of Science".
Cheryl Walker, Ph.D., is a Professor in the Departments of Molecular and Cellular Biology, Medicine, and Molecular and Human Genetics at Baylor College of Medicine. She serves as Director of the Center for Precision Environmental Health and Co-Leader of the Chromatin Biology Program at the Dan L Duncan Comprehensive Cancer Center. Her research focuses on gene-environment interactions, epigenomics, and the molecular mechanisms underlying diseases such as cancer, fibroids, and non-alcoholic fatty liver disease (NAFLD). Key areas include the role of chromatin remodelers like SETD2 in genomic stability and their dual functions in cytoskeletal dynamics. She has pioneered studies on how early-life environmental exposures, such as endocrine-disrupting chemicals (EDCs), reprogram the epigenome to increase disease susceptibility later in life. Dr. Walker’s work is funded by NIH and DOD grants, including leadership of the TaRGET II Consortium for environmental epigenomics. Her lab employs cutting-edge technologies like ChIP-seq and RNA-seq to study epigenetic reprogramming. Notable contributions include discoveries linking SETD2 methylation to microtubule stability and genomic integrity, and identifying epigenetic signatures of environmental exposures in health disparities research. Education: Ph.D. in Molecular Biology Affiliations: Baylor College of Medicine, Gulf Coast Center for Precision Environmental Health Her awards include election to the National Academy of Medicine and fellowships in the American Association for the Advancement of Science (AAAS) and American Thoracic Society (ATS). The lab actively collaborates on translational projects, including biomarker development and disaster-related health studies following events like Hurricane Harvey. Key Research Themes: Epigenetic drivers of cancer and fibrosis Environmental epigenomics and disease risk Chromatin-cytoskeleton cross-talk in disease
Brian D. Gregory is a Professor of Biology at the University of Pennsylvania's School of Arts & Sciences. His research focuses on RNA modifications, computational biology, and plant genetics, particularly studying how RNA modifications regulate gene expression in plants and animals. He holds a Ph.D. from Harvard University (2005) and a B.S.A. from the University of Arizona (2000). Research Interests: RNA epitranscriptomics (e.g., m6A, NAD+ caps) RNA secondary structure and protein interactions Genomic approaches to study plant stress responses Development of high-throughput sequencing tools like PIP-seq Recent Work Highlights: Recent studies include analyzing pathogen-induced RNA modifications' role in plant immunity (Plant Cell 2023), global RNA structure/protein interaction mapping, and epitranscriptomic dynamics in drought tolerance. His lab's work bridges computational methods with molecular genetics to uncover post-transcriptional regulatory mechanisms. Lab & Collaborations: The Gregory Lab uses Arabidopsis thaliana as a primary model organism but also explores animal systems. They collaborate with institutions like Cornell University and have developed protocols published in Current Protocols in Molecular Biology. Teaching: BIOL 4231: Genome Sciences and Genomic Medicine BIOL 6010: Communication for Biologists
Dr Amin Ardestani , Senior Lecturer in Metabolic Signaling at the Biomedical Institute for Multimorbidity (BIM), Hull York Medical School (HYMS) , specializes in unraveling molecular mechanisms of pancreatic β-cell failure in diabetes. His research program identifies novel therapeutic targets through signal transduction studies in metabolic disorders. Bachelor's in Biology, Tarbiat Moalem University (2004) Master's in Biochemistry, Institute of Biochemistry and Biophysics (2007) PhD in Biology, University of Bremen (2013) Junior Group Leader at University of Bremen (2014-2023) Research focuses on Hippo and mTOR signaling pathways in β-cell biology, autoimmunity, and regeneration. His work bridges mechanistic biology with drug discovery for diabetes, with significant findings on PHLPP1/2 phosphatases and MST1/2 kinases. Recent publications highlight therapeutic strategies for β-cell protection , including small molecule inhibitors (e.g., MST1/2 inhibitors) and metabolic enzyme modulation (LDHA). Collaborative studies explore SARS-CoV-2 interactions with pancreatic cells and cross-talk between acinar and β-cells in diabetes. 2019 JDRF Advanced Postdoctoral Fellowship 2018 Impulse grant & Career Advancement Award 2017 Early Investigators awards (Endocrine Society, EFSD/Lilly Programme) 2014 Albert Renold Fellowship & Bremer Studienpreis Professional roles include Editorial Board Member at Scientific Reports and Associate Editor at Frontiers in Endocrinology . He reviews grants for DFG, Diabetes UK, and ISF, and evaluates manuscripts for top-tier journals like Cell Metabolism and Nature Communications.
Jesper Velgaard Olsen is a Professor and Deputy Center Director at the University of Copenhagen's Novo Nordisk Foundation Center for Protein Research (CPR) and leads the Olsen Group. His research focuses on quantitative, high-resolution mass spectrometry-based proteomics, particularly in characterizing signaling networks regulated by phosphorylation and other post-translational modifications. The group develops advanced offline peptide fractionation and enrichment methods combined with high-resolution Orbitrap tandem mass spectrometry to improve robustness and reproducibility in proteomic analysis. The Olsen Group investigates functional selectivity in cell signaling, where different growth factors binding to the same receptor activate distinct pathways. They identified tyrosine phosphorylated residues as molecular switches determining cell fate and optimized workflows enabling deep human proteome analysis comparable to RNA-seq. Their work spans technology development and biological applications in diseases like acute myeloid leukemia. Key group members include PhD Fellows, PhD Students, and Researchers such as Agnete Witness Præst Jensen, Charlotte Hjort, and Kristina Bennet Emdal. For collaboration or inquiries, contact Olsen via email jesper.olsen@cpr.ku.dk .
Professor Susan Brooks is a faculty member at Oxford Brookes University in the School of Biological and Medical Sciences . Her research focuses on glycobiology , cancer progression , and the role of extracellular vesicles in metastasis. Professor of Cell Biology Director of Researcher Development Focus on breast and ovarian cancer Specialized in glycosylation mechanisms Research Interests : Dr. Brooks' work explores how aberrant glycosylation of proteins and glycans influences cancer cell behavior, including metastasis and drug resistance . Her recent studies examine extracellular vesicles as diagnostic tools and therapeutic targets. Article Trends : Over 25 years, Dr. Brooks has published 15+ articles on glycosylation patterns in breast and ovarian cancer. Key areas include lectin binding , miRNA regulation , and radiation-induced metastatic changes . Her work bridges cell biology and clinical applications .
Nikolaus Rajewsky is a leading Professor at the Max Delbrück Center for Molecular Medicine (MDC) and Charité – Universitätsmedizin Berlin , where he founded and directs the Berlin Institute for Medical Systems Biology (BIMSB) . His lab integrates experimental (biochemistry, molecular biology) and computational (bioinformatics, physics) approaches to study RNA regulation in gene expression , with applications to developmental biology, regeneration, neurodegenerative diseases, and cancer . Using model systems like C. elegans , planaria, and human brain organoids, his team pioneers cutting-edge methods such as MirDeep , DistMap , and FLAM-seq for RNA analysis. His research focuses on single-cell transcriptomics , spatial RNA sequencing , and circular RNA (circRNA) regulation , revealing novel roles for circRNAs like CDR1as in neuropsychiatric disorders. Recent work includes 3D tumor microenvironment mapping and computational modeling of RNA metabolism in diseases. Scientific Awards : Gottfried Wilhelm Leibniz Prize (2012) EMBO Membership (2010) Honorary PhD, Sapienza University of Rome (2014) Berlin Science Award (2009) His team's recent articles highlight breakthroughs in 3D spatial transcriptomics , circRNA degradation mechanisms , and mitochondrial disease modeling using human brain organoids. The lab actively collaborates with clinical partners across Charité and European institutions, driving the LifeTime initiative for cell-based interceptive medicine.
